GPR88 impairs the signaling of kappa opioid receptors in a heterologous system and in primary striatal neurons

dc.contributor.authorRivas‐Santisteban, Rafael
dc.contributor.authorLillo, Jaume
dc.contributor.authorGarrigós, Claudia
dc.contributor.authorNavarro Brugal, Gemma
dc.contributor.authorFranco Fernández, Rafael
dc.date.accessioned2025-12-10T16:33:16Z
dc.date.available2025-12-10T16:33:16Z
dc.date.issued2025-03-01
dc.date.updated2025-12-10T16:33:17Z
dc.description.abstractThe physiological role of GPR88, an orphan G protein-coupled receptor (GPCR) predominantly expressed in the striatum, remains unclear, despite its altered expression in parkinsonian animal models. GPR88 is known to interact with other GPCRs. Specifically, GPR88 expression inhibits signaling mediated by the μ-opioid receptor in cells coexpressing both receptors. The effect of GPR88 on the kappa-opioid receptor (KOR) is less understood. In this study, we examine the interaction between GPR88 and KOR, and the impact of GPR88 expression on KOR-mediated signaling in heterologous cells and primary striatal neurons. Bioluminescence resonance energy transfer and proximity ligation assays revealed an interaction between GPR88 and KOR. Functional assays showed that GPR88 antagonized the effects of U69,593, a selective KOR agonist, on forskolin-stimulated cAMP levels, β-arrestin-2 recruitment, and phosphorylation of extracellular signal-regulated kinases (ERK1/2) in HEK-293T cells coexpressing both receptors. In primary striatal neurons, GPR88 and KOR complexes were observed, with KOR activation effects enhanced when GPR88 expression was suppressed using RNA interference. These results suggest that GPR88 and KOR are coexpressed in striatal neurons, where GPR88 inhibits KOR activation. Notably, the GPR88-KOR heteromer was more prevalent in dopamine D1-receptor-containing neurons of the direct pathway of the basal ganglia. Given the roles of KORs in dopamine release, motor function regulation, and pain and reward perception, the GPR88-KOR interaction warrants further investigation in the context of neuropathic pain, Parkinson's disease, and neuropsychiatric disorders.
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec752793
dc.identifier.issn0028-3908
dc.identifier.pmid39613254
dc.identifier.urihttps://hdl.handle.net/2445/224802
dc.language.isoeng
dc.publisherElsevier Ltd.
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.neuropharm.2024.110242
dc.relation.ispartofNeuropharmacology, 2025, vol. 265
dc.relation.urihttps://doi.org/10.1016/j.neuropharm.2024.110242
dc.rightscc-by-nc (c) Rivas‐Santisteban, Rafael et al., 2025
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.classificationOpiacis
dc.subject.classificationMalaltia de Parkinson
dc.subject.otherOpioids
dc.subject.otherParkinson's disease
dc.titleGPR88 impairs the signaling of kappa opioid receptors in a heterologous system and in primary striatal neurons
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
873831.pdf
Mida:
4.22 MB
Format:
Adobe Portable Document Format